(Press-News.org) A large international study has found that spironolactone, a medication for high blood pressure and heart failure, does not reduce the risk of heart-related death or hospitalizations in people with kidney failure receiving dialysis, despite earlier smaller studies suggesting benefit.
The findings were published on August 14 in The Lancet and presented at ERA Congress 2025.
The study enrolled 2,538 participants from 143 dialysis centres across 12 countries, making it the largest trial to date on spironolactone in people receiving dialysis. All participants had been on dialysis for at least three months and were either over 45 years old, or over 18 with diabetes.
“In people with normal kidney function, spironolactone reduces cardiovascular events. However, people receiving dialysis might not respond the same way to treatments proven effective in the general population,” said Michael Walsh, principal investigator of the study and senior scientist at the Population Health Research Institute (PHRI), a joint institute of McMaster University and Hamilton Health Sciences. “We launched the ACHIEVE study to determine the safety and effectiveness of spironolactone in people with kidney failure.”
Researchers tested whether a low daily dose (25 mg) of spironolactone could block aldosterone, a hormone that causes heart remodeling, fibrosis, and raises cardiovascular risk. They wanted to see if this treatment could lower the risk of cardiovascular death or hospitalization for heart failure in patients with kidney failure. “Aldosterone plays a harmful role in heart disease, and its levels tend to be high in dialysis patients,” Walsh said. “That’s why we thought spironolactone might help.”
Instead, the drug showed no cardiovascular benefit, and it increased the risk of severe hyperkalaemia, a rise in blood potassium levels that can lead to irregular heart rhythms or even death in extreme cases. “Earlier studies suggested this type of medication might help people on dialysis, but they were small and had short follow-ups, unlike our large ACHIEVE study.”
The trial began recruiting in 2018 and concluded in December 2024. Of the 3,565 patients recruited, 2,538 who tolerated the drug during a seven-week run-in period were randomly assigned to receive either 25 mg of spironolactone daily or a placebo. The trial was stopped early for futility after an independent monitoring committee determined there was little chance of seeing a meaningful benefit.
Cardiovascular death or hospitalization for heart failure occurred in 258 patients in the spironolactone group, compared to 276 in the placebo group. The difference was not statistically significant. The study noted a potential difference in these incidents between men and women, although more research is needed to understand why:
Men: 163 (spironolactone) vs. 201 (placebo)
Women: 95 (spironolactone) vs. 75 (placebo)
Severe hyperkalaemia occurred more often in the spironolactone group: 6.6 per cent of patients in the spironolactone group, compared to 4.5 per cent in the placebo group. “This can be a serious safety concern in an already vulnerable group,” Walsh added.
Globally, an estimated 2.5 million people receive dialysis for kidney failure. Heart disease is the leading cause of death in this population, responsible for about 40 per cent of all deaths.
“We really hoped that spironolactone could make a difference for people on dialysis,” said Walsh. “While the results are not what we wanted, they provide much-needed clarity. This study moves us one step closer to finding effective and safe treatments for a group that urgently needs them.”
ACHIEVE was funded by the Canadian Institutes of Health Research, Medical Research Future Fund, Health Research Council, British Heart Foundation, PHRI, St. Joseph’s Healthcare Hamilton, Accelerating Clinical Trials Canada, CanSOLVE CKD, and Dalhousie Department of Medicine.
_____________________________________________________________________
For Media Inquiries:
To arrange an interview with Michael Walsh, please contact him at mwwalsh@mcmaster.ca.
For additional assistance or to obtain an embargoed copy of the study, reach out to Adam Ward, media relations officer with McMaster University’s Faculty of Health Sciences, at warda17@mcmaster.ca.
END
Global study finds heart failure drug spironolactone fails to lower cardiovascular risk in dialysis patients
2025-08-14
ELSE PRESS RELEASES FROM THIS DATE:
Deprivation and transport density linked to increased suicide risk in England
2025-08-14
*Embargoed links to the paper, regional data, and additional quotes are available at the end of this press release*
IMPERIAL COLLEGE LONDON PRESS RELEASE
Peer Reviewed / Observational study / People
An analysis of suicide rates in England has shown how factors like deprivation and transport density are linked to regional increases in suicide risk.
The first of its kind study, led by researchers at Imperial College London, UCL and the London School of Economics and Political Science (LSE), looked at suicide trends in England from 2002 to 2022 combined with the ...
Flatworms can replace rats for breakthrough brain studies
2025-08-14
Tiny pond worms could help find new ways to treat schizophrenia, develop understanding around drug addiction and test new medicines for mental illnesses – all while reducing the number of mice and rats used in early medical research.
Scientists from the University of Reading say that planaria - harmless flatworms found in ponds and rivers - react to brain medicines in ways similar to rodents. When given haloperidol, a drug used to treat mental health conditions, the worms became much less active, ...
Plastic from plants: FAMU-FSU College of Engineering professor uses material in plant cell walls to make versatile polymer
2025-08-14
In Ho Yong Chung’s laboratory, magic is at work — plants turn into plastics.
In new research, Chung, an associate professor in the FAMU-FSU College of Engineering, showed for the first time the possibility of using lignin, a material found in plant cell walls, and carbon dioxide to create a new kind of polyurethane, a polymer used in various applications for its ability to regulate heat, flexibility during processing and strength as a finished product.
The work was published in ACS Sustainable Chemistry & Engineering.
“We’ve ...
Leaders at Huntsman Cancer Institute drive theranostics expansion to transform cancer care
2025-08-14
Huntsman Cancer Institute at the University of Utah (the U) announces leadership team appointments overseeing clinical and research efforts in theranostics, an innovative approach to radiation treatment for cancer that combines diagnostics and therapeutics.
Heloisa Soares, MD, PhD, Huntsman Cancer Institute medical oncologist and associate professor of internal medicine at the U, will serve as medical director of the theranostics program.
Theranostics is a powerful new way to both find and treat cancer. It uses radioactive drugs—called radiopharmaceuticals—that ...
Thin films, big science: FSU chemists expand imaging possibilities with new X-ray material
2025-08-14
Most people picture a doctor checking for a broken bone when they think of an X-ray. But the technology is just as important in places like airport security, manufacturing, quality control and scientific research, each with its own criteria for size and shape.
A team led by Florida State University Professor of Chemistry and Biochemistry Biwu Ma has developed a new form for X-ray materials that can meet the needs of large-area applications, changing out complex crystal structures for an adaptable and scalable thin-film detector. The work was published in Angewandte Chemie.
“We took a material we developed and made it better,” Ma said. “This ...
66th Supplement to the Check-list of North American Birds publishes today in Ornithology
2025-08-14
CHICAGO — August 14, 2025 — The 66th Supplement to the American Ornithological Society’s (AOS’s) Check-list of North American Birds, published today in Ornithology, includes several significant updates to the classification of bird species found in North America, Central America, and the Caribbean.
A few highlights from the supplement, detailed below, include species splits for Myiarchus nuttingi, Vireo gilvus, and Larus argentatus; the addition of subfamilies in the Laridae for white-terns and noddies; and a merging of three families ...
Canadian crops beat global emissions—even after 17 trips across the Atlantic
2025-08-14
Canadian-grown wheat, canola and peas have some of the lowest carbon footprints in the world—so low that, in some cases, they could be shipped to Europe 17 times before matching the emissions of the same crops grown there.
The study out of UBC Okanagan, published in Nature Food, compared the carbon footprints of these crops from Canada, France, Germany, Australia and the United States using the ISO 14067 standard.
Led by Dr. Nicole Bamber of UBCO’s Irving K. Barber Faculty of Science, the research ...
ORC2 regulation of human gene expression shows unexpected breadth and scale
2025-08-14
BIRMINGHAM, Ala. – Origin-recognition complex, or ORC, plays an unexpectedly broad role in the regulation of human cell gene expression, according to a study in the journal Cell Reports.
“This is the first detailed study of how and where ORC regulates epigenetics and gene expression in human cells,” said Anindya Dutta, Ph.D., leader of the study and chair of the University of Alabama at Birmingham Department of Genetics. “The unanticipated scale and breadth of the regulation opens new chapters in ORC biology.”
The six-subunit complex was discovered ...
Researchers track how iron deficiency disrupts photosynthesis in crucial ocean algae
2025-08-14
The next time you breathe, consider this: photosynthesis of algae, powered by iron dust in the ocean, made it possible.
Now, a new Rutgers University study published in the Proceedings of the National Academy of Sciences pulls back the curtain on this vital process.
Iron is a critical micronutrient for marine phytoplankton, the microscopic algae that form the foundation of the ocean’s food webs. It is deposited into the world’s oceans as dust from deserts and arid areas as well as from glacial meltwater.
“Every other breath you take includes oxygen from the ocean, ...
A Mount Sinai-Led team creates model for understanding how the brain’s decision-making is impacted in psychiatric disorders
2025-08-14
Scientists from the Icahn School of Medicine at Mount Sinai, working in collaboration with a team from the University of Texas at El Paso, have developed a novel computational framework for understanding how a region of the brain known as the striatum is involved in the everyday decisions we make and, importantly, how it might factor into impaired decision-making by individuals with psychiatric disorders like post-traumatic stress disorder and substance use disorder.
In a study published in Nature Communications [10.1038/s41467-025-61466-x] on August 14, the team reported that modulating activity ...